Clinical Trial Update: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Seleno-L Methionine with Axitinib and Pembrolizumab for clear cell renal cell carcinoma, including metastatic disease, is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Pembrolizumab (pembrolizumab)
• Seleno-L Methionine (selenium-containing L-methionine)

Snippet

Sponsor: Mohammed Milhem | Conditions: Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING